2 drug(s) with this reaction
557 total reports
Cardio Respiratory Arrest has been reported as an adverse reaction across 2 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 557 adverse event reports mention cardio respiratory arrest in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with cardio respiratory arrest, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have cardio respiratory arrest listed in their FDA adverse event reports, sorted by report count:
In addition to cardio respiratory arrest, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
2 drug(s) manufactured by Abbvie Inc have cardio respiratory arrest listed in their FDA adverse event reports: PARICALCITOL, SEVOFLURANE.
There are a combined 557 reports of cardio respiratory arrest across 2 Abbvie Inc drug(s) in the FDA adverse event database.